N.W., Suite 200
Washington, District Of Columbia 20006
is an associate in King & Spalding’s Washington, D.C., office and a member of the FDA & Life Sciences Practice Group. He has assessed a variety of regulatory compliance issues for manufacturers of drugs and medical devices. Specifically, he has assisted in advising companies on state law compliance issues, development and implementation of comprehensive compliance programs, fraud and abuse issues, and advertising and promotion practices. Mr. Bohnenkamp provides counsel to the Ad Hoc State Law Compliance Group (a coalition of pharmaceutical, biotechnology, and medical device manufacturers) on a variety of laws and regulations, including state marketing code of conduct laws, gift prohibition laws, marketing costs disclosure laws, and prescriber data privacy laws, as well as the federal Physician Payment Sunshine provisions.
Prior to joining King & Spalding, Mr. Bohnenkamp held several health care administrative and legal residencies, where he assisted with analysis of medical staff and hospital bylaws, development of corporate compliance plans, issues related to hospital joint ventures, and various other legal and operational issues.
In a joint-degree program, Mr. Bohnenkamp received his J.D., magna cum laude, from Saint Louis University School of Law, and his M.H.A., highest distinction, from Saint Louis University School of Public Health. He also served two years as a Lead Editor of the American Health Lawyers Association Journal of Health Law and received a Health Law Certificate. Mr. Bohnenkamp graduated from Indiana University with a B.A. in psychology, highest distinction, as a member of Phi Beta Kappa.
“Collecting and Reporting Clinical Spend,” 6th Annual Forum on Sunshine and Aggregate Spend, Washington, D.C. (August 16, 2012)
“Tracking and Reporting State Requirements Beyond Sunshine,” Forum on Sunshine, State Laws and Aggregate Spend, San Diego, CA (April 16, 2012)
“Transparency Reporting Under the Physician Payment Sunshine Regulations,” 21st Annual Health Law and Policy Forum, Atlanta, GA (March 19, 2012)
“Operating in a Fish Bowl: Navigating Legal and Regulatory Compliance in the Age of Transparency,” Pharmaceutical Sales Training & Development Conference, Atlanta, GA (March 19, 2012)
“Capturing and Reporting Data for Research Activities Under CMS’s Proposed Sunshine Rule,” Aggregate Spend Reporting of Clinical Trial Payments Workshop, Bedminster, NJ (March 13, 2012)
“First Sunlight: Understanding the New Federal Physician Payments Sunshine Proposed Rule,” Healthcare Roundtable, Washington, D.C. (January 12, 2012)
“The Impact of Transparency on Thought Leader Relationships,” Maximizing Outcomes from Thought Leader Relationships, Boston, MA (October 18, 2011)
“How will Transparency and Disclosure Impact Sales and Marketing,” 2011 Life Sciences Forum: Transformation and Innovation, New York, NY (September 29, 2011)
"Here Comes the Sun[shine]: Preparing for the Physician Payment Sunshine Act," Pharmaceutical & Medical Device Sales & Marketing Compliance Conference, Chicago, IL (July 18, 2011)
"Understanding State Marketing Laws and Impending Federal Sunshine Requirements," Medical Device & Diagnostics Sales Training & Development Conference, Dallas, TX (March 1, 2011)
"Implementing a Comprehensive Aggregate Spend and Disclosure Solution to Ensure Compliance with US and International Regulations," Live Webcast (November 4, 2010)
"Understanding New State Pharmaceutical Marketing Laws and Their Effect on Your Overall Sales Performance," Pharmaceutical Sales Training & Development Conference, Chicago, IL (September 14, 2010)
"What's Next for the States: Pushing the Envelope on Disclosure and Gift Bans," 2010 National Disclosure Summit, Washington, D.C. (March 4, 2010)
“The Changing Nature of Life Sciences/Provider/Professional Relationships,” Illinois Association of Healthcare Attorneys 27th Annual Health Law Symposium, Chicago, IL (October 21, 2009)
"State Data Mining Restrictions - What's Next?," CBI and Pharmaceutical Executive’s 2nd Annual Leadership Summit on Evolving the Pharma Sales Model, Philadelphia, PA (September 24, 2009)
"How State Laws Affect Your Company," 2009 Regulatory Affairs Professionals Society Annual Conference, Philadelphia, PA (September 12, 2009)
Brian Bohnenkamp, Seth Lundy & Ami Patel, “States Want Healthier Professional Relationships: More State Legislatures are Tightening Restrictions on the Promotional Activities of Medical Device Companies,” MX Medtech Executive, April 2010
Brian Bohnenkamp & Christina Markus, “Evolving Expectations for Transparency of Industry-Healthcare Provider Relationships,” American Health Lawyers Association, Life Sciences Newsletter, Volume 3, Issue 2, Oct. 2009
Brian Bohnenkamp & Nikki Reeves, “How The New Massachusetts Marketing Code Of Conduct And Disclosure Requirements Will Impact Medical Device Manufacturers,” American Health Lawyers Association, 7 Health Lawyers Weekly 14, Apr. 10, 2009
|Areas of Practice||1) FDA & Life Sciences and 2) Healthcare Industry|
|Law School||J.D., magna cum laude, St. Louis University|
|Education||B.A., highest distinction, Indiana University|
|Bar Member / Association||State bar of District of Columbia,State bar of Illinois|
|Most recent firm||King & Spalding LLP|
Bricker & Eckler LLP, one of central Ohio’s leading law firms, is headquartered in the historic Old, Old Post Office in downtown Columbus, with branch offices located throughout Ohio. This positio...
Health Policy Analyst
Description of Position The Health Policy Analyst is responsible for analyzing federal and state law and policy related to healthcare access. He/ She supports TD&P Consulting’s legal team in pr...
Paralegal Duties: Provides substantive legal work in support of the Group General Counsel and the team within the legal department who perform work in the areas of Legal Operations. Drafting various ...
|+ View more jobs|
Ms. Fitzgerald represents employers in a wide range of industries, including the entertainment, financial services, hospitality, manufacturing, retail, and transportation industries.
Ms. Shander advises public and private company clients as well as private equity funds, with an emphasis on mergers and acquisitions, dispositions, and financing transactions.